Clinical trial
An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/Levodopa Extended-release Tablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed Conditions
NCT05128175 is registered in ClinicalTrials.gov with Shanghai WD Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/Levodopa Extended-release Tablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed Conditions
- Lead sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 29, 2021
- Completion date
- December 9, 2021
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.